ECP effective in the long-term

Article

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Dr Lima and colleagues conducted a long-term retrospective study of ECP in refractory glaucomas that included 539 eyes of 485 patients. Each subject underwent one ECP and were followed-up for a minimum five-year period, and retrospectively reviewed. Limbal or pars plana ECP was performed for 210 degrees with scleral depression of the ciliary body.Preoperative IOP was 37.9±6.4 mmHg, diminishing to 15.7±8.5 mmHg. The average number of surgeries preoperatively was 2.2 and the mean number of preoperative medications was 3.9±0.6, reducing postoperatively to 1.5±1.1. Success at one and five years postoperatively (defined as IOP between 5 and 22 mmHg) was 92.6% and 78.8%, respectively. Complications included fibrin exudates (21.5%), failed corneal graft (19.7%), hyphaema (10.7%), immediate postoperative IOP spike (9.8%), choroidal detachment (5.8%), phthisis (2.4%), retinal detachment (1.5%) and hypotony (1.3%).

The authors of this study believe that the results demonstrate the effectiveness of ECP as a long-term management approach for refractory glaucoma and recommend that it be considered as a first-line treatment.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.